Lipocalin-2 drives neuropsychiatric and cutaneous disease in MRL/lpr mice.

ABSTRACT:

Introduction

Approximately 20-40% of patients with systemic lupus erythematosus (SLE) experience neuropsychiatric SLE (NPSLE), which often manifests as cognitive dysfunction and depression. Currently, there are no approved treatments for NPSLE because its underlying mechanisms are unclear. Identifying relevant mediators and understanding their contribution to pathogenesis are crucial for developing targeted treatment options. Lipocalin 2 (LCN2) is a multifunctional acute-phase protein that plays important roles in immune cell differentiation, migration, and function. LCN2 has been implicated in models of neuroinflammatory disease.

Methods

We generated an LCN2-deficient MRL/lpr mouse to evaluate the effects of LCN2 on this classic NPSLE model. To evaluate the effects of LCN2

SUBMITTER: Garcia SJ 

PROVIDER: S-EPMC11466786 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature